Gerben Moolhuizen
Chief Executive Officer at ISA Pharmaceuticals BV
Profile
Gerben Moolhuizen is currently the Chief Executive Officer at ISA Pharmaceuticals BV.
Previously, he held positions as Director-Business Development at Pharming Group NV, Vice President-Business Development at PrimaGen Holding BV, and Chief Business Officer at Dr. Reddy's Research & Development BV.
He has an MBA from Erasmus University Rotterdam and a graduate degree from the University of Utrecht.
Gerben Moolhuizen active positions
Companies | Position | Start |
---|---|---|
ISA Pharmaceuticals BV
ISA Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology ISA Pharmaceuticals BV operates as a clinical-stage immunotherapy company. The firm develops novel therapeutic vaccines for cancer and infectious diseases. Its product portfolio builds on its proprietary SLP-technology (Synthetic Long Peptide) for the development of therapeutic vaccines. The firm holds the exclusive rights to LUMC's patent families for amongst others, the development of therapeutic vaccines. The company was founded by Cornelis J. M. Melief in 2004 and is headquartered in Leiden, the Netherlands. | Chief Executive Officer | - |
Former positions of Gerben Moolhuizen
Companies | Position | End |
---|---|---|
PHARMING GROUP N.V. | Corporate Officer/Principal | - |
PrimaGen Holding BV
PrimaGen Holding BV Miscellaneous Commercial ServicesCommercial Services PrimaGen Holding BV designs and develops molecular diagnostic tests. The firm conducts tests in the fields of mitochondrial toxicity, drug development toxicology screening, HIV monitoring, DFS paper technology, oncology and virus discovery. It also develops in monitoring toxic side effects of antiviral medication and for diagnosing and monitoring certain forms of cancer. The company was founded in November 2001 and is headquartered in Amsterdam, the Netherlands. | Corporate Officer/Principal | - |
Dr. Reddy's Research & Development BV
Dr. Reddy's Research & Development BV Pharmaceuticals: MajorHealth Technology Dr. Reddy's Research & Development BV is engaged in the development and manufacture of injectable pharmaceutical products. It provides formulation, development, drug delivery, and clinical material manufacturing services to biotech and pharmaceutical companies worldwide. The company was founded by Joost J. M. Holthuis on July 20, 1995 and is headquartered in Leiden, Netherlands. | Corporate Officer/Principal | - |
Training of Gerben Moolhuizen
University of Utrecht | Graduate Degree |
Erasmus University Rotterdam | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
PHARMING GROUP N.V. | Health Technology |
Private companies | 3 |
---|---|
Dr. Reddy's Research & Development BV
Dr. Reddy's Research & Development BV Pharmaceuticals: MajorHealth Technology Dr. Reddy's Research & Development BV is engaged in the development and manufacture of injectable pharmaceutical products. It provides formulation, development, drug delivery, and clinical material manufacturing services to biotech and pharmaceutical companies worldwide. The company was founded by Joost J. M. Holthuis on July 20, 1995 and is headquartered in Leiden, Netherlands. | Health Technology |
PrimaGen Holding BV
PrimaGen Holding BV Miscellaneous Commercial ServicesCommercial Services PrimaGen Holding BV designs and develops molecular diagnostic tests. The firm conducts tests in the fields of mitochondrial toxicity, drug development toxicology screening, HIV monitoring, DFS paper technology, oncology and virus discovery. It also develops in monitoring toxic side effects of antiviral medication and for diagnosing and monitoring certain forms of cancer. The company was founded in November 2001 and is headquartered in Amsterdam, the Netherlands. | Commercial Services |
ISA Pharmaceuticals BV
ISA Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology ISA Pharmaceuticals BV operates as a clinical-stage immunotherapy company. The firm develops novel therapeutic vaccines for cancer and infectious diseases. Its product portfolio builds on its proprietary SLP-technology (Synthetic Long Peptide) for the development of therapeutic vaccines. The firm holds the exclusive rights to LUMC's patent families for amongst others, the development of therapeutic vaccines. The company was founded by Cornelis J. M. Melief in 2004 and is headquartered in Leiden, the Netherlands. | Health Technology |
- Stock Market
- Insiders
- Gerben Moolhuizen